20-gauge safer than 25-gauge surgery

Article

Patients undergoing 25-gauge vitreoretinal surgery are more likely to experience postoperative serous choroidal effusion and hypotony than patients undergoing 20-gauge procedures.

Patients undergoing 25-gauge vitreoretinal surgery are more likely to experience postoperative serous choroidal effusion and hypotony than patients undergoing 20-gauge procedures, according to a report published in the October issue of Retina.

Saad Shaikh and co-workers from Rollins College and Central Florida Retina Consultants, Florida, US compared complication rates between two groups of 129 eyes treated with primary 25- or 20-gauge vitreoretinal surgery. Average follow-up was 9.1 months and 14.3 months in the 25- and 20-gauge groups, respectively.

The researchers found that both groups had similar rates of intraoperative complications, which were mainly rhematogenous in nature. A total of 46% of patients, in both groups, experienced cataract progression. Eyes treated with 25-gauge procedures, had a significantly higher incidence of postoperative complications; 7.9% developed hypotony and serous choroidal effusions compared with just 1.6% of the 20-gauge treated eyes. Two eyes in the 25-gauge group developed endophthalmitis.

It was the conclusion of the authors that 25-gauge surgery is more likely to result in postoperative complications than 20-gauge surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.